Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,870 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Acute Pain, Burns, Adverse Drug Event, Respiratory Depression, Nausea and Vomiting, Postoperative
Interventions: Oliceridine, Historical opioid use; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diabetes, Obesity
Interventions: Detemir; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 31 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Brain Metastases
Interventions: 18F-Fluciclovine (Axumin) PET/CT; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Intervention-carbon Monoxide Alarm + Educational Tool, Control- Usual Care Flyer on Carbon Monoxide
Interventions: Educational Tool & Carbon Monoxide Alarm; Behavioral
Lead sponsor: Lara McKenzie; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions: OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist; Drug · Combination Product · Other
Lead sponsor: Epkin; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Beverly Hills, California • Santa Monica, California • Houston, Texas

Conditions: Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
Interventions: urine Resazurin Reduction Ratio, USQNB; Diagnostic Test · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 2 Diabetes
Interventions: telehealth-based clinical pharmacy intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 2 Diabetes, Mental Health Issue, Quality of Life, Weight Loss
Interventions: CBT-based lifestyle intervention; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Renal Impairment
Interventions: Fruquintinib; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Diabetes Mellitus in Pregnancy, Diabetes, Gestational, Diabetes Mellitus, Type 2
Interventions: Glycemic Targets; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Stroke
Interventions: Virtual reality based dance group, Active Comparator: Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Adenocarcinoma
Interventions: Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet; Behavioral
Lead sponsor: Stephen Freedland; Other
Eligibility: Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Durham, North Carolina

Conditions: Cardiac Conduction and Repolarization
Interventions: Custirsen, Placebo, Moxifloxacin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Nicotine Addiction
Interventions: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subjects
Interventions: lemborexant, Loestrin, famotidine, fluconazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gestational Diabetes
Interventions: Glyburide, Glucovance; Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions: Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment; Other · Device
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Healthy
Interventions: Lofexidine HCl; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Small Fiber Neuropathy, Fabry Disease, Ehlers Danlos Syndrome, Mitochondrial Disease
Interventions: Sudoscan, Skin biopsy, QSART; Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Depression
Interventions: Coenzyme Q10; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 55 Years to 89 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions: Nicotinamide riboside (NR), Placebo; Dietary Supplement · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 39 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Pancreatitis
Interventions: Creon36™; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 30 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Surgery
Interventions: Lantus, Insulin; Drug · Other
Lead sponsor: Tamra Dukatz; Other
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Royal Oak, Michigan • Troy, Michigan

Search by objective public record fields.

Oliceridine in Patients With Acute Burn Injuries

Insulin Detemir in Obesity Management

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

Emergency Department Brief Intervention to Increase Carbon Monoxide Detector Use

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Rapid UTI Diagnostics in Lower Urinary Tract Dysfunction Among Catheter Users

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Rural Area Pharmacist Intervention for Diabetes

Community-based CBT and T2D in Latino Population

Fruquintinib Renal Impairment Study

Glycemic Targets for Pregnant Women With GDM and T2DM

Active Balance and Cardio Care Intervention on Physical and Cardiovascular Health in People With Chronic Stroke

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Nicotinic Receptor Levels After Stopping Smoking

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Glyburide vs Glucovance in the Treatment of GDM

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

Lofexidine Food Effect Study in Healthy Volunteers

Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan

Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Fat Malabsorption in Chronic Pancreatitis

Perioperative Insulin Glargine Dosing Study